Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants

[1] Nair H(2010)Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 1545-1555

[2] Nokes DJ(2009)A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection BMC Infect Dis 9 106-77

[3] Gessner BD(2014)Respiratory syncytial virus infection in high-risk infants — an update on palivizumab prophylaxis Open Microbiol J 11 71-606

[4] Dherani M(2000)Correlation between illness severity and risk factors for respiratory syncytial virus infection Chin J Pediatr 38 603-468

[5] Madhi SA(2012)Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis J Crit Care 27 464-350

[6] Singleton RJ(2014)Epidemiology and risk factors for severe respiratory syncytial virus infections requiring pediatric intensive care admission in Hong Kong children Infection 42 343-341

[7] Morris SK(2014)Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou, China Pediatr Infect Dis J 33 337-700

[8] Dzolganovski B(2013)Risk factors for hospitalization due to lower respiratory tract infection in preterm infants on palivizumab prophylaxis Iran J Pediatr 23 693-349

[9] Beyene J(2013)Respiratory syncytial virus and asthma: speeddating or long-term relationship? Curr Opin Pediatr 25 344-90

[10] Sung L(2007)Guidelines for management of childhood community acquired pneumonia (for trial implementation) Chin J Pediatr (Chin) 45 83-62

[1] Nair H(2010)Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 1545-1555

[2] Nokes DJ(2009)A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection BMC Infect Dis 9 106-77

[3] Gessner BD(2014)Respiratory syncytial virus infection in high-risk infants — an update on palivizumab prophylaxis Open Microbiol J 11 71-606

[4] Dherani M(2000)Correlation between illness severity and risk factors for respiratory syncytial virus infection Chin J Pediatr 38 603-468

[5] Madhi SA(2012)Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis J Crit Care 27 464-350

[6] Singleton RJ(2014)Epidemiology and risk factors for severe respiratory syncytial virus infections requiring pediatric intensive care admission in Hong Kong children Infection 42 343-341

[7] Morris SK(2014)Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou, China Pediatr Infect Dis J 33 337-700

[8] Dzolganovski B(2013)Risk factors for hospitalization due to lower respiratory tract infection in preterm infants on palivizumab prophylaxis Iran J Pediatr 23 693-349

[9] Beyene J(2013)Respiratory syncytial virus and asthma: speeddating or long-term relationship? Curr Opin Pediatr 25 344-90

[10] Sung L(2007)Guidelines for management of childhood community acquired pneumonia (for trial implementation) Chin J Pediatr (Chin) 45 83-62